Safety Data Keeps Momenta/Sandoz’ Generic Lovenox In Play With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Response to immunogenicity concern could boost chances for FDA approval next year.
You may also be interested in...
Sanofi Sues FDA, Claiming Agency Exceeded Its Authority In Approving Enoxaparin
Company claims the agency approved the generic although the innovator drug had not been fully characterized, but odds are against a Sanofi win in court.
Sanofi Sues FDA, Claiming Agency Exceeded Its Authority In Approving Enoxaparin
Company claims the agency approved the generic although the innovator drug had not been fully characterized, but odds are against a Sanofi win in court.
The Year Ahead For Generic Drugs: The Calm Before The Storm
Several blockbuster drugs will face generic competition for the first time in 2010, but overall the year marks a reprieve for brand drug makers, one last chance to grip the ledge before tumbling over the patent cliff in 2011